Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Linked open drug data for pharmaceutical research and development.

Samwald M, Jentzsch A, Bouton C, Kallesøe CS, Willighagen E, Hajagos J, Marshall MS, Prud'hommeaux E, Hassenzadeh O, Pichler E, Stephens S.

J Cheminform. 2011 May 16;3(1):19. doi: 10.1186/1758-2946-3-19.

2.

Family pediatrics: report of the Task Force on the Family.

Schor EL; American Academy of Pediatrics Task Force on the Family..

Pediatrics. 2003 Jun;111(6 Pt 2):1541-71.

PMID:
12777595
3.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
4.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. German.

PMID:
19034813
5.

Developing good scientific publishing practices: one pharmaceutical company's perspective.

Dowsett SA, Van Campen LE, Bednar LA.

Curr Med Res Opin. 2010 Jun;26(6):1249-54. doi: 10.1185/03007991003748880.

PMID:
20350148
6.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

7.

Diagnosis and management of dental caries throughout life.

National Institutes of Health (U.S.)..

NIH Consens Statement. 2001 Mar 26-28;18(1):1-23. Review.

PMID:
11699634
8.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
9.

Impact of cost sharing on prescription drugs used by Medicare beneficiaries.

Goedken AM, Urmie JM, Farris KB, Doucette WR.

Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003.

PMID:
20511109
10.

Open-access public-private partnerships to enable drug discovery--new approaches.

Müller S, Weigelt J.

IDrugs. 2010 Mar;13(3):175-80. Review.

PMID:
20191434
11.

Report of the ASHP Task Force on Caring for Patients Served by Specialty Suppliers.

Caselnova D 3rd, Donley K, Ehlers D, Hyduk AE, Koontz SE, Nowobilski-Vasilios A, Pawlicki KS, Poikonen JC, Poremba AC, Sasser CL, Schell KH, Schwab JL, Swinarski D, Chen D, Kirschenbaum B, Armitstead J.

Am J Health Syst Pharm. 2010 Oct 1;67(19):1650-8. doi: 10.2146/ajhp100085.

PMID:
20852168
13.

Committee on Natural Toxins and Food Allergens. Marine and freshwater toxins.

Hungerford JM.

J AOAC Int. 2005 Jan-Feb;88(1):299-313.

PMID:
15759755
14.

EMEA and the evaluation of health-related quality of life data in the drug regulatory process.

Papanicolaou S, Sykes D, Mossialos E.

Int J Technol Assess Health Care. 2004 Summer;20(3):311-24. Review.

PMID:
15446761
15.

Spending on new drug development1.

Adams CP, Brantner VV.

Health Econ. 2010 Feb;19(2):130-41. doi: 10.1002/hec.1454.

PMID:
19247981
16.

Identification and assessment of ongoing trials in health technology assessment reviews.

Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, Hyde C.

Health Technol Assess. 2004 Nov;8(44):iii, 1-87. Review.

17.

The economics of pediatric formulation development for off-patent drugs.

Milne CP, Bruss JB.

Clin Ther. 2008 Nov;30(11):2133-45. doi: 10.1016/j.clinthera.2008.11.019. Review.

PMID:
19108801
18.

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

Breman JG, Alilio MS, Mills A.

Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15. Review.

19.

Web resources for drug toxicity.

Wolfgang GH, Johnson DE.

Toxicology. 2002 Apr 25;173(1-2):67-74. Review.

PMID:
11955684
20.

Treatments for fatigue in multiple sclerosis: a rapid and systematic review.

Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C.

Health Technol Assess. 2000;4(27):1-61. Review.

Items per page

Supplemental Content

Support Center